STOCKHOLM, SWEDEN / ACCESS Newswire / February 24, 2025 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB (publ) (FN ...

StockNews.com initiated coverage on shares of Ayala Pharmaceuticals (NASDAQ:ADXS – Free Report) in a research note released on Sunday morning. The brokerage issued a sell rating on the stock. Ayala ...

We recently published a list of 10 Best Immunology Stocks To Buy Now. In this article, we are going to take a look at where ...

Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer ...

STOCKHOLM, SWEDEN / ACCESS Newswire / February 24, 2025 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB (publ) (FN STO:ALZCUR) ), a pharmaceutical company that develops candidate drugs for ...

Investment analysts at StockNews.com began coverage on shares of Ayala Pharmaceuticals (NASDAQ:ADXS – Get Free Report) in a report released on Saturday. The firm set a “sell” rating on the stock.

Healx has dosed the first patient in a Phase II trial assessing its lead pipeline candidate HLX-1502 in patients with neurofibromatosis type 1 (NF1), while the FDA approved SpringWorks Therapeutics’ ...

A recent study published in eLife offers a new perspective on the development of Alzheimer’s disease, suggesting that the condition may be triggered by disruptions in how the brain processes proteins.

It offers OGSIVEO (nirogacestat), an oral small molecule gamma secretase inhibitor for the treatment of desmoid tumors; and GOMEKLI (mirdametinib), an oral small molecule inhibitor of MEK1 and ...